SunHo (China) BioPharmaceutical Co., Ltd.
A biopharmaceutical company focused on discovering, developing and commercializing first-in-class/best-in-class biologics that modulate the immune microenvironment by directly regulating innate and adaptive immune systems.
Last updated September 1, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
SunHo (China) BioPharmaceutical Co., Ltd. is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class/best-in-class biologics that modulate the immune microenvironment by directly regulating innate and adaptive immune systems. The company develops various types of immunotherapies, including antibody-cytokines for the treatment of cancer and autoimmune diseases. Its proprietary technology platforms include the AIC™ platform for antibody-cytokine fusion proteins, the AEA™ platform for enhanced antibody-dependent cellular cytotoxicity, and the AIM™ platform for innate immunity-stimulating multispecific antibodies. The company has a global innovative and differentiated pipeline of 9 programs, with 6 in clinical development, and employs 117 people, with 62.2% of R&D personnel holding master's degrees or above. It has established GMP-compliant production facilities with four production lines for drug substance, a total bioreactor capacity of 1600 liters, and a 5000-liter bioreactor line installed and qualified. Its formulation facilities include a liquid injection filling line and a lyophilized powder line.
History
SunHo (China) BioPharmaceutical Co., Ltd. is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class/best-in-class biologics that modulate the immune microenvironment by directly regulating innate and adaptive immune systems. The company develops various types of immunotherapies, including antibody-cytokines for the treatment of cancer and autoimmune diseases. Its proprietary technology platforms include the AIC™ platform for antibody-cytokine fusion proteins, the AEA™ platform for enhanced antibody-dependent cellular cytotoxicity, and the AIM™ platform for innate immunity-stimulating multispecific antibodies. The company has a global innovative and differentiated pipeline of 9 programs, with 6 in clinical development, and employs 117 people, with 62.2% of R&D personnel holding master's degrees or above. It has established GMP-compliant production facilities with four production lines for drug substance, a total bioreactor capacity of 1600 liters, and a 5000-liter bioreactor line installed and qualified. Its formulation facilities include a liquid injection filling line and a lyophilized powder line.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/sunho-china-biopharmaceutical-co-ltd-china · Editorial policy · How profiles are compiled